Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Clinical trial NCT03258567 · RECRUITING

Trial details

NCT number: NCT03258567
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Epstein-Barr Virus Infections Lymphoma Lymphoproliferative Disorder Disorders, Lymphoproliferative

Start date: 2018-04-26
Primary completion: 2029-06-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.